Corvus Pharmaceuticals (FRA:C17) Institutional Ownership: 54.93% (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €11.18
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Institutional Ownership?

Corvus Pharmaceuticals FRA:C17 -6.52% 34 Institutional Ownership is 54.93% as of Jul. 29, 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Corvus Pharmaceuticals's institutional ownership is 54.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Corvus Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Corvus Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 87.97%.

Corvus Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Institutional Ownership Chart

Corvus Pharmaceuticals Historical Data

The historical data trend for Corvus Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 42.03 42.15 42.82 45.24 49.59 51.62 59.12 52.42 51.68 54.93
FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 54.93% mean?
Corvus Pharmaceuticals (FRA:C17) has a Institutional Ownership of 54.93% as of Jul. 29, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Corvus Pharmaceuticals and its competitors.
Is Corvus Pharmaceuticals' Institutional Ownership too high?
Corvus Pharmaceuticals' current Institutional Ownership is 54.93%. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Institutional Ownership compare to MGTX and WVE?
Corvus Pharmaceuticals' Institutional Ownership of 54.93% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Institutional Ownership is 54.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Institutional Ownership of 54.93%. The current Institutional Ownership is 54.93%. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Institutional Ownership is 54.93% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.18
Price